Skip to main content
. 2019 Mar 5;16:17. doi: 10.1186/s12986-019-0344-9

Fig. 8.

Fig. 8

Effects of PPARγ agonist and antagonist on CMKLR1 level in the livers (a) and gastrocnemius (b) of EDM rats. The exercise-induced decreases of CMKLR1 in the livers (a) and gastrocnemius (b) of EDM rats were reversed by PPARγ antagonist GW9662 at protein levels. PPARγ agonist pioglitazone further strengthened the reduction of CMKLR1 in the gastrocnemius (b) instead of the livers (a) of EDM rats. The blots of CMKLR1 were quantified by Tanon software and normalized against β-actin or GAPDH, then the normalized numbers were compared between different groups (bottom). DM: diabetes mellitus; EDM: exercised DM; EDP: EDM + pioglitazone; EDG: EDM + GW9662. *P<0.05, **P<0.01 vs DM. #P<0.05, ##P<0.01 vs EDM